Key points are not available for this paper at this time.
A novel inhibitor of the protein PPARG, which is overexpressed in most cases of advanced urothelial carcinoma, led to tumor shrinkage in most patients with high PPARG expression who received the drug FX-909. In addition, some responding patients had elevated levels of CD4+ T cells and circulating chemokines and cytokines, suggesting that the drug attenuates PPARG-mediated immune suppression.
A Tue, study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: